Expert Consensus on Perioperative Immunotherapy for Local Advanced Non-Small Cell Lung Cancer
Bin Qiu,Kaican Cai,Chun Chen,Jun Chen,Ke-Neng Chen,Qi-Xun Chen,Chao Cheng,Tian-Yang Dai,Junqiang Fan,Zhaohui Fan,Jian Hu,Wei-Dong Hu,Yun-Chao Huang,Ge-Ning Jiang,Jie Jiang,Tao Jiang,Wen-Jie Jiao,He-Cheng Li,Qiang Li,Yong-De Liao,Hong-Xu Liu,Jun-Feng Liu,Lunxu Liu,Yang Liu,Hao Long,Qing-Quan Luo,Hai-Tao Ma,Nai-Quan Mao,Xiao-Jie Pan,Fengwei Tan,Li-Jie Tan,Hui Tian,Dong Wang,Wen-Xiang Wang,Li Wei,Nan Wu,Qing-Chen Wu,Jiaqing Xiang,Shi-Dong Xu,Lin Yang,Hao Zhang,Lanjun Zhang,Peng Zhang,Yi Zhang,Zhenfa Zhang,Kunshou Zhu,Yuming Zhu,Sang-Won Um,In-Jae Oh,Yusuke Tomita,Satoshi Watanabe,Takeo Nakada,Nobuhiko Seki,Toyoaki Hida,Shinji Sasada,Junji Uchino,Haruhiko Sugimura,Said Dermime,Federico Cappuzzo,Stefania Rizzo,William Chi-Shing Cho,Pierfilippo Crucitti,Filippo Longo,Kye Young Lee,Dirk De Ruysscher,Ben G. L. Vanneste,Muhammad Furqan,Jessica C. Sieren,Sai Yendamuri,Kenneth W. Merrell,Julian R. Molina,Giulio Metro,Raffaele Califano,Stefano Bongiolatti,Mariano Provencio,Paul Hofman,Shugeng Gao,Jie He
DOI: https://doi.org/10.21037/tlcr-21-634
2021-01-01
Translational Lung Cancer Research
Abstract:The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary